UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


 

FORM 8-K

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 20, 2012


BIOHEART, INC.

(Exact name of registrant as specified in its charter)


Florida

(State or other jurisdiction of incorporation)

 

 

 

 

 

 

1-33718

 

65-0945967

  

 

 

(Commission File Number)

 

(IRS Employer Identification No.)

 


13794 N.W. 4th Street, Suite 212
Sunrise, Florida 33325

(Address of principal executive offices, including zip code)


(954) 835-1500

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


 

 

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





 ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 20, 2012, Bioheart, Inc. (the “Company”) terminated the employment of Catherine Sulawske-Guck, its Chief Operating Officer.


  






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

  

BIOHEART, INC.

 

 

 

Date: March 23, 2012

  

By:

 

/s/ Mike Tomas

 

  

Name:

 

Mike Tomas

 

  

Title:

 

Chief Executive Officer